Strategic Planning

Smart Hospitals Become the New Standard of Care
Data and Information Smart Hospitals Become the New Standard of Care

The very walls of a modern hospital are beginning to think, transforming sterile rooms once defined by beeping monitors and call bells into dynamic ecosystems of proactive and deeply personalized patient care. This shift represents more than an upgrade; it is a fundamental redefinition of the

Trend Analysis: State-Level Healthcare Reform
Public Policy Trend Analysis: State-Level Healthcare Reform

As the intricate gears of national healthcare policy turn slowly, a powerful new engine of change is emerging at the state level, where lawmakers are directly confronting local crises with tailored, innovative solutions. New Mexico's recent legislative session offers a compelling case study in

Can VBC Bridge the Kidney Care Equity Gap?
Care Can VBC Bridge the Kidney Care Equity Gap?

With his extensive background in medical technology and a deep focus on driving innovation, Faisal Zain has become a leading voice in the application of value-based care to solve some of healthcare’s most persistent challenges. Today, we'll delve into his insights on transforming care for c

Why Did Mount Sinai Choose Microsoft's AI Scribe?
Technology Why Did Mount Sinai Choose Microsoft's AI Scribe?

The escalating burden of administrative tasks, particularly clinical documentation, has become a central challenge in modern healthcare, contributing significantly to physician burnout and diverting focus from direct patient care. In a strategic move to address this issue, New York's Mount

Danaher Leads Diagnostic Expansion in New Markets
Business Danaher Leads Diagnostic Expansion in New Markets

Beneath the surface of daily healthcare, a quiet revolution is taking shape, orchestrated by a corporate giant that has mastered the art of specialized yet comprehensive market influence. Danaher Corporation, a name well-known in investment circles but less so to the general public, is methodically

Eli Lilly Acquires Orna in a $2.4B Cell Therapy Deal
Business Eli Lilly Acquires Orna in a $2.4B Cell Therapy Deal

The multi-billion-dollar price tag attached to a pharmaceutical acquisition often captures headlines, but the true significance of Eli Lilly's $2.4 billion deal for Orna Therapeutics lies in the revolutionary science it aims to command. This is not merely a financial transaction; it represents

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later